Recrutamento encerrado
FASE
Número Europeu 2019-002089-11
CMBG453B12301 STIMULUS-MDS2
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Detalhes
Destaques